A case report of BCR-ABL(+) acute myeloid leukemia and literature review

BCR-ABL(+) acute myeloid leukemia (AML) is considered a rare AML subtype with a short median survival time and poor prognosis. Currently, there is no unified standard treatment regimen for this disease, which complicates clinical diagnosis, treatment and medication selection. Case reports on this AML subtype remain relatively scarce to date. In this study, we present a case of BCR-ABL(+) AML that was treated with a TKI in combination with chemotherapy to induce remission, followed by allogeneic hematopoietic stem cell transplantation (Allo-HSCT). We also review the relevant literature to shed light on treatment strategies for BCR-ABL(+) AML and provide strong support for Allo-HSCT as a therapeutic option for this subtype.